Switching to Unboosted Atazanavir Improves Glucose Tolerance in Highly Pretreated HIV-1 Infected Subjects

European Journal of Endocrinology - United Kingdom
doi 10.1530/eje-06-0648
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Bioscientifica

Related search

No Difference in Effectiveness of Treatment Simplification to Boosted or Unboosted Atazanavir Plus Lamivudine in Virologically Suppressed in HIV-1-infected Patients

PLoS ONE
Multidisciplinary
2018English

External Validation of the Bilirubin–Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients

AAPS Journal
Pharmaceutical Science
2012English

High-Carbohydrate–low-Glycaemic Index Dietary Advice Improves Glucose Disposition Index in Subjects With Impaired Glucose Tolerance

British Journal of Nutrition
MedicineNutritionDietetics
2002English

Height and Glucose Tolerance in Adult Subjects

Diabetologia
Internal MedicineEndocrinologyMetabolismDiabetes
1991English

Safety of Darunavir and Atazanavir in HIV-infected Children in Europe and Thailand

Antiviral Therapy
Infectious DiseasesPharmacology
2015English

Dyslipidemia in HIV-1 Infected Subjects With Short Term Usage of Highly Active Antiretroviral Therapy (HAART) in Benin City, Nigeria

Nigerian Journal of Basic and Applied Sciences
2017English

Effector Mechanisms in HIV-1 Infected Elite Controllers: Highly Active Immune Responses?

Antiviral Research
VirologyPharmacology
2010English

Raltegravir With Unboosted Atazanavir 300 Mg Twice Daily in Antiretroviral Treatment-Experienced Participants

Journal of the International Association of Physicians in AIDS Care
2009English

Hyperbilirubinemia in Atazanavir Treated HIV-infected Patients: The Impact of the UGT1A1*28 Allele

Pharmacogenomics and Personalized Medicine
Molecular MedicinePharmacology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy